Sign in Subscribe

Archive

A collection of 364 issues

Latest

FIT Performance Data Now Available for Adults 55 and Younger

Skip to content The CRC Digest ▪ SCREENING FIT Performance Data Now Available for Adults 55 and Younger A cross-sectional German study of 1,724 participants aged 55 or younger assessed fecal immunochemical test (FIT) diagnostic performance at various fecal hemoglobin cutoffs for detecting advanced neoplasia, addressing a critical data gap

Six-Marker Blood Test Shows Promise for CRC Screening in High-Risk Patients

Skip to content The CRC Digest ▪ SCREENING Six-Marker Blood Test Shows Promise for CRC Screening in High-Risk Patients A prospective study evaluated a multi-target DNA methylation panel (Septin9 region 1, BCAT1, IKZF1, BCAN, VAV3, Septin9 region 2) assessed in plasma samples for colorectal cancer risk stratification, offering a potential non-invasive

CRC Research Update — July 27, 2026

Today's colorectal cancer research highlights

End-of-Life Care Trends Show Shift Toward Home and Hospice

Skip to content The CRC Digest End-of-Life Care Trends Show Shift Toward Home and Hospice Among 75,428 early-onset CRC decedents from 1999-2020, the proportion dying at home or hospice facilities increased from 48.3% to 66.6%, though disparities persist for Black patients. (Journal of Gastrointestinal Cancer) This content

China Issues Expert Consensus on Early-Onset CRC Management

Skip to content The CRC Digest China Issues Expert Consensus on Early-Onset CRC Management New guidelines address the unique needs of younger patients, including fertility preservation, sexual function, and long-term quality of life considerations. (Zhonghua Wei Chang Wai Ke Za Zhi) This content is informational only and does not constitute

PLOD2 Protein Linked to Tumor Growth in Colorectal Cancer

Skip to content The CRC Digest ◇ RESEARCH PLOD2 Protein Linked to Tumor Growth in Colorectal Cancer Preclinical research using single-cell RNA sequencing found that PLOD2, often overexpressed in colorectal cancer, has been implicated in promoting tumor growth and epithelial-mesenchymal transition. Functional assays in CRC cell lines with PLOD2 knockdown showed

Real-World Study Examines Immune-Related Side Effects in Neoadjuvant Immunotherapy

Skip to content The CRC Digest ♥ LIVING WITH CRC Real-World Study Examines Immune-Related Side Effects in Neoadjuvant Immunotherapy A multicenter study of 452 colorectal cancer patients who received neoadjuvant immunotherapy analyzed the incidence of immune-related adverse events and perioperative outcomes following curative surgery. (Zhonghua Wei Chang Wai Ke Za Zhi)

Study Assesses New FIT Buffer for Hemoglobin Preservation

Skip to content The CRC Digest ▪ SCREENING Study Assesses New FIT Buffer for Hemoglobin Preservation A study assessed the faecal hemoglobin preservation capacity of a new faecal immunochemical test buffer formulation (SOC4) at varying temperatures and storage times. Fresh faecal samples were collected using buffers containing either the standard (SOC3)

Phase III Trial Compares Total Neoadjuvant Therapy Approaches in High-Risk Rectal Cancer

Skip to content The CRC Digest ◆ TRIAL DATA Phase III Trial Compares Total Neoadjuvant Therapy Approaches in High-Risk Rectal Cancer A multicenter, randomized phase III trial evaluated total neoadjuvant therapy with long-course radiotherapy versus chemoradiotherapy in patients with high-risk locally advanced rectal cancer. (Journal of Clinical Oncology) This content is

DHODH Identified as Metabolic Vulnerability in PIK3CA-Mutant Colorectal Cancer

Skip to content The CRC Digest DHODH Identified as Metabolic Vulnerability in PIK3CA-Mutant Colorectal Cancer Preclinical research identifies dihydroorotate dehydrogenase (DHODH) as a selective metabolic dependency in PIK3CA-mutant CRC; DHODH inhibition reduces cancer cell self-renewal and tumor initiation by disrupting PI3K-AKT signaling. (Cell Reports) This content is informational only and